There is a mechanism in our act that would enable a hearing panel of the board to compel that type of information from the company if it felt it was germane, and if it required that information to make a ruling on whether the price of the drug was, in fact, excessive. But there have been all manner of drug transparency bills proposed before various state legislatures in the U.S., whereby they are trying to compel companies to open up the books and actually reveal how much they are spending on these drugs and whether there is some proportionate relationship between R and D and prices. To date, that has really failed. I think a lot of people in the know are not big supporters of that, because they are concerned that if you just regulate prices on the basis of profit, you turn pharmaceuticals into a utility. That's the argument.
On November 6th, 2018. See this statement in context.